NCT03923868 - D-0120 Safety and PK/PD Study in China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Hyperuricemia or Gout

Interventions

DRUG

D-0120

D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days

Trial Locations (6)

Site 04, Bengbu

Site 03, Nanjing

Site 07, Nanjing

Site 01- The second affiliated hospital of zhejiang university school of medicine, Hangzhou

Site 06, Huzhou

Site 05, Wenzhou